Haemostatix has developed a new class of peptide based coagulant, or "haemostat", for the control of bleeding. The company has pioneered a new approach to haemostasis that is based on a peptide that binds to the protein fibrinogen, inducing the rapid and targeted formation of clots. This innovative technology platform is being used to develop a pipeline of topical products to treat surgical bleeding with further applications in tissue repair and regenerative medicine.
The haemostat market is worth $2.5billion and is expanding globally at 6-8% per annum. Growth in several market segments, and emerging economies has exceeded 10% per annum. The market leader is blood derived thrombin, a relatively fragile molecule requiring storage in a dry or frozen form. Haemostatix's peptide-based coagulants are blood-free, have greater stability enabling the formulation of ready-to-use liquids and gels, and have a mode of action that is faster than thrombin-mediated clotting. Haemostatix's pipeline includes:
PeproStat™ Liquid, a topical liquid haemostat that is applied to wounds to control bleeding during surgery. PeproStat has a novel mode of action that is fast and effective. The peptide-based coagulant is manufactured from blood-free components and is formulated as a ready-to-use solution, to be used with commercially available resorbable sponges. Current products are typically blood-derived and often require re-constitution or thawing prior to use. PeproStat™ Liquid has been successfully evaluated in a clinical trial at four hospitals in the UK, following authorisation from the MHRA. The trial was in liver surgery patients and generated both safety and efficacy data. The FDA and EMA have been consulted with respect to the completion of clinical program.
HXP12 ReadyFlow™, a flowable gel-based haemostat that is applied with a syringe and nozzle enabling less accessible wounds to be treated, as well as wounds with uneven surfaces. HXP12 ReadyFlow is composed of a heat-stable peptide active substance mixed with a transparent particulate gel and pre-filled in a ready-to-use syringe. Current products in this rapidly expanding market segment require 8 preparation steps prior to use, are blood derived, and opaque, obscuring the wound site. HXP12 ReadyFlow won first prize in the pan European Emerging Technology Competition run by the Royal Society of Chemistry.
Haemostatix Ltd is based at Biocity Nottingham, UK and is a subsidiary of Ergomed plc (LSE AIM listed ERGO)